Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science (RC2 Clinical Trial Optional)

The National Institutes of Health is announcing a limited competition for High Impact Specialized Innovation Programs in Clinical and Translational Science. The purpose of this program is to support the development and demonstration of unique hub capabilities, research platforms, and/or resources to address critical gap areas and/or roadblocks in clinical and translational science at awarded Clinical and Translational Science Awards (CTSA) Program Hubs. • The program will support the development of innovative solutions to address critical gaps in clinical and translational science. • The program is limited to eligible organizations that have an active Clinical and Translational Science Award (UM1) application or award. • The program will provide funding for up to two years, with the possibility of renewal. • The program will support the development of unique hub capabilities, research platforms, and/or resources. • The program will lay a strong foundation for future adoption and/or dissemination of capabilities to additional CTSA Program Hubs.